Background
==========

Atherosclerosis and its complications, such as myocardial infarction and stroke, are the leading cause of morbidity and mortality in the developed world \[[@b1-medscimonit-17-7-cr381]\]. Stress, tobacco smoking, alcohol consumption, hypertension, diabetes mellitus, obesity, insulin resistance and dyslipidemia have been identified as important risk factors predisposing to atherosclerosis \[[@b2-medscimonit-17-7-cr381],[@b3-medscimonit-17-7-cr381]\]. At an early stage of disease, endothelial cells dysfunction causes the release of vasoactive molecules, which stimulate inflammatory responses and recruitment/migration of leukocytes into the arterial wall \[[@b4-medscimonit-17-7-cr381]\]. Macrophage stimulation leads to the secretion of cytokines, growth factors and other mediators, which promote smooth muscle cell proliferation and migration \[[@b5-medscimonit-17-7-cr381]\]. In later stages, smooth muscle cells activation stimulates the release of pro-inflammatory cytokines, which, combined with the secretion of matrix metalloproteinases (MMPs) and procoagulant factors, results in chronic inflammatory state and plaque instability \[[@b5-medscimonit-17-7-cr381],[@b6-medscimonit-17-7-cr381]\]. The resulting chronic inflammatory state and the enrichment of lipid-laden macrophages (foam cells) contribute to the development of advanced atherosclerotic lesions, which ultimately causes luminal obstruction and plaque rupture, leading to thrombus formation and, eventually, ischemic events \[[@b6-medscimonit-17-7-cr381]\]. The multi-factorial nature of atherosclerosis involves chronic inflammation at every step from initiation to progression, suggesting that certain clinical risk factors may contribute to the pathogenesis of disease by aggravating the underlying inflammatory process \[[@b7-medscimonit-17-7-cr381]\].

PPAR-γ is a ligand-activated transcription factor, which belongs to the nuclear receptor superfamily \[[@b8-medscimonit-17-7-cr381]\]. Upon ligand activation, PPAR-γ forms heterodimers with its nuclear receptor partners, Retinoid X Receptors (RXRs) and binds to specific PPAR response elements (PPREs) in the promoter region of the target genes, regulating gene function through dissociation of co-repressors and recruitment of co-activators \[[@b9-medscimonit-17-7-cr381],[@b10-medscimonit-17-7-cr381]\]. RXRs are common heterodimerization partners for several nuclear receptors beyond PPARs, including thyroid receptors (TRs), vitamin D receptor (VDR), and liver, farnesoid and pregnane X receptors (LXR, FXR and PXR, respectively) \[[@b11-medscimonit-17-7-cr381]\]. The RXR family includes 3 distinct subtypes, termed as RXR-α, -β and -γ; however, it still remains unclear whether their nuclear partners, such as PPAR-γ, exhibit a marked preference for 1 of them \[[@b12-medscimonit-17-7-cr381],[@b13-medscimonit-17-7-cr381]\]. Moreover, it has not yet been elucidated whether their role is restricted to acting as heterodimerization partners for nuclear receptors, or if there is actually a separate RXR-mediated signalling pathway \[[@b12-medscimonit-17-7-cr381],[@b13-medscimonit-17-7-cr381]\].

Currently, PPAR-γ constitutes a key regulator of glucose homeostasis and adipogenesis and is a promising therapeutic target for the treatment of patients with type 2 diabetes mellitus \[[@b14-medscimonit-17-7-cr381],[@b15-medscimonit-17-7-cr381]\]. Two synthetic PPAR-γ activators, pioglitazone and rosiglitazone, which belong to the thiazolidinedione (TZD) class, have successfully been introduced in the market as oral antidiabetic agents to attenuate insulin resistance associated with obesity, hypertension and impaired glucose homeostasis \[[@b16-medscimonit-17-7-cr381],[@b17-medscimonit-17-7-cr381]\]. Pleiotropic functions beyond this limit, such as anti-proliferative and anti-inflammatory effects against several pathophysiological states, including neoplasia, ischemia/reperfusion injury, gestational diseases and arthritis, are currently being explored in clinical studies \[[@b18-medscimonit-17-7-cr381]--[@b23-medscimonit-17-7-cr381]\]. An increasing body of evidence from preclinical and clinical studies has further supported that PPAR-γ ligands, and especially TZDs, exert a broad spectrum of anti-inflammatory and anti-proliferative effects on all cell types participating in the development of cardiovascular diseases \[[@b24-medscimonit-17-7-cr381]--[@b26-medscimonit-17-7-cr381]\]. Importantly, PPAR-γ was shown to be expressed in atherosclerotic lesions and in all vascular wall apparent cell types \[[@b27-medscimonit-17-7-cr381]--[@b30-medscimonit-17-7-cr381]\]. PPAR-γ ligand treatment was also reported to attenuate the development and progression of atherosclerotic lesions in several animal models \[[@b24-medscimonit-17-7-cr381],[@b31-medscimonit-17-7-cr381]--[@b34-medscimonit-17-7-cr381]\]. Moreover, TZDs treatment was shown to reduce carotid artery intima/media thickness in patients with type 2 diabetes \[[@b24-medscimonit-17-7-cr381],[@b30-medscimonit-17-7-cr381],[@b35-medscimonit-17-7-cr381]\].

Taking into consideration the extensive use of PPAR-γ agonists in patients at high risk for cardiovascular diseases, the understanding of PPAR-γ function in the vasculature is not only of basic interest, but also carries important clinical implications. However, there is no comprehensive research so far concerning the clinical significance of PPAR-γ and its nuclear partner, RXR-α, in patients with advanced carotid atherosclerotic lesions. In view of the above considerations, our study aimed to assess the immunohistochemical expression of PPAR-γ and RXR-α in different cellular populations (macrophages, smooth muscle cells and endothelial cells), localized within advanced atherosclerotic lesions in patients that underwent carotid endarterectomy for vascular repair. Correlations of this differential cellular expression of PPAR-γ and RXR-α with patients' medical history, risk factors and medication intake were examined.

Material and Methods
====================

Clinical material
-----------------

One hundred thirty-four (134) consecutive patients of Greek ethnicity that underwent carotid endarterectomy in Laikon Hospital between January 2006 and December 2008 were eligible for this study. The study was approved by the Hospital Ethics Committee, and informed consent was obtained from all participants. Indication for surgery was a symptomatic carotid stenosis ≥50% or an asymptomatic carotid stenosis ≥70% according to ESVS guidelines \[[@b36-medscimonit-17-7-cr381]\]. Preoperatively, patients had either carotid duplex ultrasound scans or digital subtraction angiograms, or both of these. Patients or plaques were defined as symptomatic when focal symptoms of cerebral ischemia were present, ipsilateral to the carotid lesions, such as transient ischemic attack (TIA), amaurosis fugax, or stroke, in the last 6 months. All patients were preoperatively on antiplatelet treatment that was interrupted 1 week before surgery.

A complete medical history, risk factors and medication intake were recorded, including: age, sex, coronary artery disease-CAD (angina pectoris, myocardial infarction and coronary artery by-pass grafting/percutaneous transluminal coronary angioplasty-CABG/PTCA), diabetes mellitus (controlled with diet, oral hypoglycemic agents or insulin; fasting glucose level ≥126mg/dL), hypercholesterolemia (total cholesterol ≥200mg/dL), hypertension (systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or self-report of high blood pressure) \[[@b37-medscimonit-17-7-cr381]\], peripheral artery disease (PAD), smoking history, and therapy with statins and angiotensin-converting enzyme (ACE) inhibitors. The demographic characteristics of the study population are summarized in [Tables 1](#t1-medscimonit-17-7-cr381){ref-type="table"} and [2](#t2-medscimonit-17-7-cr381){ref-type="table"}.

Carotid specimens' histopathology
---------------------------------

The carotid plaque surgical specimens were collected intra-operatively immediately after endarterectomy and fixed in 10% buffered formalin for 24 hours. After decalcification, if necessary, specimens were embedded in paraffin wax using conventional techniques, cut transversely at 4ìm and stained with hematoxylin-eosin (H-E). After staining with H-E, 3 to 4 sections per specimen were examined. The section with plaque ulceration or thrombus, the most stenotic segment of the plaques, or both sections, were chosen for further analysis. Plaques were classified into 2 groups: (1) thrombotic plaques including (1a) plaque rupture, (1b) plaque erosion, and (1c) calcified nodule, and (2) plaques without acute thrombosis divided into: (2a) vulnerable and (2b) stable plaques \[[@b38-medscimonit-17-7-cr381]\].

Immunohistochemistry
--------------------

Immunostainings for PPAR-γ and RXR-α were performed on paraffin-embedded carotid plaque surgical specimens using a commercially available mouse (IgG~1~) monoclonal antibody (E-8) that recognizes the carboxy terminus of human PPAR-γ (Santa Cruz Biochemicals, Santa Cruz, CA, USA), reacting with PPAR-γ1 and -γ2, and another rabbit polyclonal antibody that recognizes human RXR-α (D-20) (Santa Cruz Biochemicals). Briefly, 4μm thick tissue sections were dewaxed in xylene and were brought to water through graded alcohols. To remove the endogenous peroxidase activity, sections were then treated with freshly prepared 0.3% hydrogen peroxide in methanol in the dark, for 30 min (minutes), at room temperature. Antigen retrieval was performed for PPAR-γ antigen detection, by microwaving slides in 10mM citrate buffer (pH 6.0) for 15 min \[[@b39-medscimonit-17-7-cr381]\]. Non-specific antibody binding was then blocked using a specific blocking reagent for 5 min (Sniper, Biocare Medical, Walnut Creek, CA, USA). The sections were then incubated for 1 hour at room temperature, with the primary antibodies PPAR-γ and RXR-α diluted 1:100 in phosphate buffered saline (PBS). After washing 3 times with PBS, sections were incubated at room temperature with biotinylated linking reagent (Biocare Medical) for 10 min, followed by incubation with peroxidase-conjugated streptavidin label (Biocare Medical) for 10 min. The resultant immune peroxidase activity was developed in 0.5% 3,3′-diaminobenzidine hydrochloride (Vector Laboratories, Peterborough, United Kingdom) for 10 min. Sections were counterstained with Harris' hematoxylin and mounted in Entellan (Merck, Darmstadt, Germany). Appropriate negative controls were performed by omitting the primary antibody and/or substituting it with an irrelevant anti-serum. As positive controls, pancreatic cancer tissue sections with known increased expression of PPAR-γ and RXR-α were used \[[@b39-medscimonit-17-7-cr381]\].

Immunohistochemical evaluation
------------------------------

The expression of PPAR-γ and RXR-α was assessed on macrophages, smooth muscle and endothelial cells of the carotid plaque specimens by 2 different observers (ST and GK) blinded to the clinical data with very good inter-observer agreement (κ=0.961, SE: 0.022). Carotid specimens were considered positive for PPAR-γ and RXR-α when more than 5% of macrophages, smooth muscle and endothelial cells were positively stained \[[@b39-medscimonit-17-7-cr381]--[@b42-medscimonit-17-7-cr381]\]. The median value of percentage expression for PPAR-γ and RXR-α in macrophages, smooth muscle and endothelial cells was used as a threshold to discriminate the carotid specimens into 2 categories: low and high expression \[[@b39-medscimonit-17-7-cr381]--[@b42-medscimonit-17-7-cr381]\]. In positively stained carotid specimens, the immunoreactivity of PPAR-γ and RXR-α was further classified according to staining intensity as mild (+), intermediate (++), and intense (+++) \[[@b39-medscimonit-17-7-cr381]--[@b42-medscimonit-17-7-cr381]\]. Specimens that exhibited percentage expression values equal to the median percentage value were considered to present low expression if their staining intensity was classified as mild (+), whereas they were considered to present high expression if their staining intensity was classified as intermediate (++) or intense (+++). In this way, we ensured that each group had a sufficient and more homogeneous number of cases in the cross-tables in order to be comparable with the other groups \[[@b39-medscimonit-17-7-cr381]--[@b42-medscimonit-17-7-cr381]\].

Plasma homocysteine and C-Reactive Protein (CRP) determination
--------------------------------------------------------------

Preoperative fasting blood samples were available for 123 patients. The blood samples were collected in Vacutainer tubes under sterile conditions. Plasma was separated from whole blood by centrifugation at 1500×g at 4°C for 10 min and the separated plasma was kept at −80°C until analysis. Plasma homocysteine levels were determined by reversed-phase High Performance Liquid Chromatography (HPLC) coupled to a fluorescence detector (ImmuChrom GmbH, Heppenheim, Germany). The albumin-bound and oxidized homocysteine was reduced and converted into a fluorescence probe in 1 step. The quantification was performed using a delivered plasma calibrator and the concentration was calculated via the internal standard method. The sensitivity of the homocysteine assay was 0.3 μmol/l. Inter- and intra-assay coefficients of variation were 1.7% to 3.5% and 0.9% to 1.0%, respectively. The manufacture's normal values are \<15 μmol/L. A concentration range from 15 to 30 μmol/L indicates lack of vitamin, while concentrations \>30 μmol/L indicate a heterozygote homocysteinemia.

Plasma C-Reactive Protein (CRP) levels were measured on the BN ProSpec nephelometer (Dade Behring, Siemens Healthcare Diagnostics) with fully automated latex particle-enhanced immunonephelometric assay, according to the manufacturer's instructions. The intra- and inter-assay CVs were less than 6% and less than 7%, respectively.

Statistical analysis
--------------------

The associations of PPAR-γ and RXR-α expression with clinical variables of medical history, risk factors and medication intake were assessed by chi-square test. Spearman's rank correlation coefficient (R~s~) was used to evaluate the linear relationships PPAR-γ and RXR-α expression. The inter-observer agreement was determined with the use of κ statistics. The *k* value is indicated including the standard error (SE). A two-tailed p\<0.05 was considered statistically significant. Statistical analysis was performed using the software package SPSS for Windows (version 11.0; SPSS Inc., Chicago, IL, USA).

Results
=======

One hundred and thirty-four patients were evaluated. Main characteristics of the patient population are depicted in [Tables 1](#t1-medscimonit-17-7-cr381){ref-type="table"} and [2](#t2-medscimonit-17-7-cr381){ref-type="table"}. The mean age was 71.02±7.98 years, and the vast majority (81%) were male. Seventy-two patients (54%) suffered from carotid atherosclerosis-related neurological event (amaurosis fugax or stroke or TIA). A thrombotic plaque was observed in 49 (37%) cases, 44 (33%) of which were ruptured. Of the remaining non-thrombotic plaques, 30 (22%) were classified as vulnerable. Thrombotic plaques were observed more frequently in patients affected by stroke, TIA or amaurosis fugax as compared to asymptomatic patients (p\<0.001).

PPAR-γ positivity in macrophages and smooth muscle cells was noted in 84 (63%) and 95 (71%) out of 134 carotid specimens, respectively. RXR-α positivity in macrophages and smooth muscle cells was noted in 129 (96%) and 133 (99%) out of 134 carotid specimens, respectively. Representative immunostainings for PPAR-γ and RXR-α protein expression in macrophages and smooth muscle cells are depicted in [Figures 1](#f1-medscimonit-17-7-cr381){ref-type="fig"} and [2](#f2-medscimonit-17-7-cr381){ref-type="fig"}, respectively. The vast majority of carotid specimens did not show positive immunoreactivity for PPAR-γ and RXR-α in endothelial cells, as only 11 (8%) cases were PPAR-γ positive and only 13 (10%) cases were RXR-α positive (data not shown). The low incidence of PPAR-γ and RXR-α immunopositivity in endothelial cells did not permit any statistical analysis with clinical variables in this cellular population (data not shown).

Low PPAR-γ expression in macrophages was significantly more frequently observed in patients with history of CAD and CABG/PTCA ([Table 1](#t1-medscimonit-17-7-cr381){ref-type="table"}, p=0.032 and p=0.007, respectively). Accordingly, a significantly increased incidence of low PPAR-γ expression in smooth muscle cells of patients presenting history of CAD or CABG/PTCA was noted ([Table 1](#t1-medscimonit-17-7-cr381){ref-type="table"}, p=0.046 and p=0.028, respectively). Low PPAR-γ expression in macrophages and smooth muscle cells was also more frequently observed in patients receiving therapy with statins, without reaching statistical significance ([Table 1](#t1-medscimonit-17-7-cr381){ref-type="table"}, p=0.056 and p=0.075, respectively). An increased incidence of low PPAR-γ expression in smooth muscle cells was also noted in patients with no evidence of hypertension, without reaching statistical significance ([Table 1](#t1-medscimonit-17-7-cr381){ref-type="table"}, p=0.082).

Symptomatic patients more frequently showed low PPAR-γ expression in smooth muscle cells compared to asymptomatic patients, without reaching statistical significance ([Table 1](#t1-medscimonit-17-7-cr381){ref-type="table"}, p=0.061). When looking within specific cerebrovascular events, patients with amaurosis fugax more frequently presented low PPAR-γ expression in smooth muscle cells compared to asymptomatic patients, at a statistically significant level (p=0.008). PPAR-γ expression in smooth muscle cells was also significantly different between asymptomatic patients and those with combined amaurosis fugax/stroke (p=0.020), as well as amaurosis fugax/TIA (p=0.028).

A significantly increased frequency of low RXR-α expression in macrophages localized within carotid atherosclerotic lesions obtained from patients presenting history of hyperlipidemia was noted ([Table 2](#t2-medscimonit-17-7-cr381){ref-type="table"}, p=0.048). Hypertensive patients more frequently showed low RXR-α expression in macrophages compared to normotensive ones ([Table 2](#t2-medscimonit-17-7-cr381){ref-type="table"}, p=0.049). Patients presenting advanced carotid stenosis grade (≥90%) exhibited significantly increased incidence of low RXR-α expression in smooth muscle cells compared to those with carotid stenosis grade \<90% ([Table 2](#t2-medscimonit-17-7-cr381){ref-type="table"}, p=0.015). Female patients more frequently presented high RXR-α expression in smooth muscle cells compared to males, without reaching statistical significance ([Table 2](#t2-medscimonit-17-7-cr381){ref-type="table"}, p=0.071).

We further statistically analyzed PPAR-γ and RXR-α expression in relation with patients' plasma homocysteine and CRP levels. Patients presenting elevated plasma CRP levels were characterized by a significantly increased incidence of low PPAR-γ expression in macrophages ([Table 3](#t3-medscimonit-17-7-cr381){ref-type="table"}, p=0.038). PPAR-γ expression down-regulation in macrophages was also more frequently observed in patients with enhanced homocysteine levels, without reaching statistical significance ([Table 3](#t3-medscimonit-17-7-cr381){ref-type="table"}, p\>0.005). PPAR-γ expression in smooth muscle cells, as well as RXR-α expression in both macrophages and smooth muscle cells did not show significant association with plasma homocysteine and CRP levels ([Table 3](#t3-medscimonit-17-7-cr381){ref-type="table"}, p\>0.005).

Spearman's correlation analysis was used to evaluate the linear relationship between PPAR-γ and RXR-α expression. PPAR-γ expression in macrophages was positively associated with RXR-α expression (R~s~=0.213, p=0.017). Accordingly, a positive association between PPAR-γ and RXR-α expression in smooth muscle cells was also noted (R~s~=0.225, p=0.011). No significant association between PPAR-γ and RXR-α expression in endothelial cells was obtained (R~s~=0.032, p=0.698).

Discussion
==========

Carotid and cerebrovascular disease have major public health implications given the associated morbidity and mortality; however, the best treatment for this disease remains uncertain. Currently, carotid endarterectomy has proven useful in primary and secondary prevention of stroke episodes in respect to patients with advanced internal carotid artery stenosis \[[@b43-medscimonit-17-7-cr381],[@b44-medscimonit-17-7-cr381]\]. However, a significant number of patients are considered at high risk for such surgical procedures and they therefore have relatively few treatment options \[[@b45-medscimonit-17-7-cr381],[@b46-medscimonit-17-7-cr381]\].

In the last few years, PPAR-γ has been recognized as a crucial player in the pathogenesis of atherosclerosis and a promising therapeutic target for the treatment of cardiovascular complications \[[@b47-medscimonit-17-7-cr381]\]. In fact, TZDs treatment was shown to attenuate the progression of carotid artery intima/media thickness, a well-described surrogate marker for cardiovascular risk \[[@b24-medscimonit-17-7-cr381],[@b48-medscimonit-17-7-cr381]\]. TZD therapy in patients undergoing coronary stent implantation was also associated with less in-stent restenosis and repeated revascularization. Importantly, cardiovascular outcome studies further suggested that pioglitazone reduced all-cause mortality, myocardial infarction, and stroke in patients with type 2 diabetes \[[@b24-medscimonit-17-7-cr381],[@b48-medscimonit-17-7-cr381]\]. Moreover, PPAR-γ expression was enhanced in neointima formed after balloon injury of rat endothelium, suggesting that PPAR-γ expression may be up-regulated in vascular cells when the vasculature is damaged \[[@b49-medscimonit-17-7-cr381]\]. At a cellular level, it has certainly been well-established that PPAR-γ is expressed in monocytes/macrophages, smooth muscle and endothelial cells localized within injured vascular wall \[[@b27-medscimonit-17-7-cr381],[@b29-medscimonit-17-7-cr381],[@b49-medscimonit-17-7-cr381],[@b50-medscimonit-17-7-cr381]\]. Notably, PPAR-γ ligands were shown to exert beneficial effects on the control of macrophage lipid metabolism and inflammatory status, which play crucial roles in atherosclerosis development and progression \[[@b24-medscimonit-17-7-cr381]--[@b26-medscimonit-17-7-cr381]\]. Emerging evidence has also implicated PPAR-γ as an essential transcriptional modulator of smooth muscle cell proliferation \[[@b51-medscimonit-17-7-cr381]--[@b53-medscimonit-17-7-cr381]\].

In this aspect, the present study aimed to assess the immunohistochemical expression of PPAR-γ and RXR-α in different cellular populations localized within advanced atherosclerotic lesions obtained from patients that underwent carotid endarterectomy for vascular repair. We showed that the incidence of low PPAR-γ expression in macrophages and smooth muscle cells was significantly increased in patients with history of CAD and CABG/PTCA. Symptomatic patients (with amaurosis fugax alone or combined amaurosis fugax/stroke or amaurosis fugax/TIA) also more frequently presented low PPAR-γ expression in smooth muscle cells compared to asymptomatic patients. The reduced levels of PPAR-γ expression may be indicative of a more pronounced disease progression, raising the possibility that PPAR-γ may be involved in carotid atherosclerotic plaque stabilization. These findings may also suggest that PPAR-γ activation could be proved to be a more effective therapeutic intervention in patients at an early stage of disease. In this context, recent studies showed that PPAR-γ mRNA levels were significantly reduced in occlusive and ectatic atherosclerotic tissues compared to arterial control ones, which was ascribed to the increased amount of cytokines in the plaque microenvironment \[[@b54-medscimonit-17-7-cr381]\]. Moreover, PPAR-γ1 expression in carotid atheromas was not down-regulated in any diabetic symptomatic patients compared to asymptomatic ones \[[@b55-medscimonit-17-7-cr381]\]. Such association was not obtained in diabetic patients, raising the possibility that certain clinical factors may affect the impact of PPAR-γ in the pathogenesis of atherosclerosis \[[@b55-medscimonit-17-7-cr381]\]. Notably, PPAR-γ 12Ala allele carriers were shown to have less widespread CAD, being also considerably protected against 10-year cardiovascular morbidity and mortality \[[@b56-medscimonit-17-7-cr381]\]. These long-term findings in patients with manifest CAD further supported an important role for PPAR-γ in determining vascular risk. We further found a significant association between PPAR-γ expression in macrophages and plasma CRP levels, which may suggest a possible interlink between carotid atherosclerosis, PPAR-γ and inflammatory infiltration associated with carotid plaque destabilization and subsequent neurologic events. In support of this view, several convincing pieces of evidence have implied a crucial role for PPAR-γ in certain inflammatory pathways related with atherosclerosis progression \[[@b25-medscimonit-17-7-cr381],[@b26-medscimonit-17-7-cr381]\].

Accordingly, we showed that RXR-α expression down-regulation was associated with pronounced disease progression in patients with advanced atherosclerotic lesions. In fact, the incidence of low RXR-α expression in macrophages was significantly increased in patients with evidence of hyperlipidemia and hypertension. Patients with advanced carotid stenosis grade also presented significant increased frequency of low RXR-α expression in smooth muscle cells. In this context, several substantial studies have revealed that RXR may be involved in the pathogenesis of atherosclerosis. More to the point, RXRs have been identified as important regulators of glucose, fatty acid and cholesterol metabolism, which are associated with common metabolic disorders such as diabetes type 2, hyperlipidaemia and atherosclerosis \[[@b57-medscimonit-17-7-cr381]\]. RXR activation by bexarotene was shown to modulate essential metabolic pathways governing atherosclerosis in mice by improving, at least in part, the circulating cholesterol distribution profile \[[@b58-medscimonit-17-7-cr381]\]. RXR activation also considerably reduced the development of atherosclerosis in apolipoprotein E^−/−^ mice \[[@b59-medscimonit-17-7-cr381]\]. Moreover, RXR agonists inhibited phorbol-12-myristate-13-acetate (PMA)-induced monocytic THP-1 cell differentiation into macrophage-like cells \[[@b60-medscimonit-17-7-cr381]\]. Notably, simultaneous PPAR-γ and RXR activation suppressed foam cell formation through enhanced cholesterol efflux despite the increased oxidized low density lipoprotein (oxLDL) uptake \[[@b61-medscimonit-17-7-cr381]\].

We further revealed that PPAR-γ expression in macrophages and smooth muscle cells was significantly associated with RXR-α expression. In this context, it should be noted that PPAR-γ forms heterodimers with RXRs in order to exert its function by regulating gene transcription or transrepression. Remarkably, RXR-α activation by 9-cis-retinoic acid (RA) synergistically enhanced the inhibition of human coronary artery vascular smooth muscle cell growth induced by PPAR-γ activation \[[@b62-medscimonit-17-7-cr381]\]. Thus, dimerization of PPAR-γ with RXR-α was required to achieve maximal suppression of coronary artery vascular smooth muscle cell growth \[[@b62-medscimonit-17-7-cr381]\]. An increased incidence of low PPAR-γ expression in macrophages and smooth muscle cells was also noted in patients receiving lipid-lowering therapy with statins. This could be ascribe to the fact that this patients' subgroup had already experienced more pronounced disease progression, such as hyperlipidemia, evidence of CABG/PTCA and elevated plasma homocysteine levels in order to receive therapy with statins.

Conclusions
===========

PPAR-γ and RXR-α immunohistochemical expression was assessed for the first time in patients with advanced carotid atherosclerotic lesions who underwent carotid endarterectomy for vascular repair and was associated with important clinicopathological parameters, such as patients' medical history, risk factors and medication intake. Low levels of PPAR-γ and RXR-α expression in both macrophages and smooth muscle cells were associated with a more pronounced disease progression in patients with advanced carotid atherosclerotic lesions. However, further research conducted on distinct patients' groups (e.g., only diabetic or non-diabetic patients, only symptomatic or asymptomatic patients, only patients with or without evidence of CAD) is required to delineate the clinical implications of PPAR-γ and RXR-α in advanced stages of carotid atherosclerosis.
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###### 

Associations of PPAR- γ expression in macrophages and smooth muscle cells with medical history, risk factors and medication intake in patients with advanced carotid atherosclerosis lesions.

  Clinical variables   N=134        PPAR-γ expression in macrophages   PPAR-γ expression in smooth muscle cells                                         
  -------------------- ------------ ---------------------------------- ------------------------------------------ ----------- ------------ ------------ -----------
                                    69 (51)                            65 (49)                                                70 (52)      64 (48)      
  **Age (mean ±SD)**   71.02±7.98   71.11±7.94                         70.75±8.07                                 0.683       71.80±7.75   70.00±8.05   0.103
  **Gender**                                                                                                      0.617                                 0.617
  Male                 109 (81)     55 (41)                            54 (40)                                                58 (43)      51 (38)      
  Female               25 (19)      14 (10)                            11 (8)                                                 12 (9)       13 (10)      
  **Carotid**                                                                                                     0.630                                 0.638
  Right                75 (56)      40 (30)                            35 (26)                                                37 (28)      38 (28)      
  Left                 59 (44)      29 (22)                            30 (22)                                                33 (25)      26 (19)      
  **Stenosis grade**                                                                                              0.862                                 0.999
  \<90%                67 (50)      34 (25)                            33 (25)                                                35 (26)      32 (24)      
  ≥90%                 67 (50)      35 (26)                            32 (24)                                                35 (26)      32 (24)      
  **Diabetes**                                                                                                    0.684                                 0.898
  No                   97 (72)      51 (38)                            46 (34)                                                51 (38)      46 (34)      
  Yes                  37 (28)      18 (13)                            19 (14)                                                19 (14)      18 (13)      
  **Hyperlipidemia**                                                                                              0.328                                 0.464
  No                   44 (33)      20 (15)                            24 (18)                                                21 (16)      23 (17)      
  Yes                  90 (67)      49 (37)                            41 (31)                                                49 (37)      41 (31)      
  **Hypertension**                                                                                                0.549                                 **0.082**
  No                   32 (24)      15 (11)                            17 (13)                                                21 (16)      11 (8)       
  Yes                  102 (76)     54 (40)                            48 (36)                                                49 (37)      53 (40)      
  **Smoking status**                                                                                              0.178                                 0.716
  No                   44 (33)      19 (14)                            25 (19)                                                22 (16)      22 (16)      
  Yes                  90 (67)      50 (37)                            40 (30)                                                48 (36)      42 (31)      
  **Statins**                                                                                                     **0.056**                             **0.075**
  No                   86 (64)      39 (29)                            47 (35)                                                40 (30)      46 (34)      
  Yes                  48 (36)      30 (22)                            18 (13)                                                30 (22)      18 (13)      
  **Antiplateles**                                                                                                0.821                                 0.273
  No                   94 (70)      49 (37)                            45 (34)                                                52 (39)      42 (31)      
  Yes                  40 (30)      20 (15)                            20 (15)                                                18 (13)      22 (16)      
  **ACES**                                                                                                        0.173                                 0.630
  No                   72 (54)      41 (31)                            31 (23)                                                39 (29)      33 (25)      
  Yes                  62 (46)      28 (21)                            34 (25)                                                31 (23)      31 (23)      
  **CAD**                                                                                                         **0.032**                             **0.046**
  No                   76 (57)      33 (25)                            43 (32)                                                34 (25)      42 (31)      
  Yes                  58 (43)      36 (27)                            22 (16)                                                36 (27)      22 (16)      
  **PAD**                                                                                                         0.254                                 0.517
  No                   97 (72)      47 (35)                            50 (37)                                                49 (37)      48 (36)      
  Yes                  37 (28)      22 (16)                            15 (11)                                                21 (16)      16 (12)      
  **CABG/PTCA**                                                                                                   **0.007**                             **0.028**
  No                   97 (72)      43 (32)                            54 (40)                                                45 (34)      52 (39)      
  Yes                  37 (28)      26 (19)                            11 (8)                                                 25 (19)      12 (9)       
  **Symptoms**                                                                                                    0.504                                 **0.061**
  No                   62 (46)      30 (22)                            32 (24)                                                27 (20)      35 (26)      
  Yes                  72 (54)      39 (29)                            33 (25)                                                43 (32)      29 (22)      

###### 

Associations of RXR-α expression in macrophages and smooth muscle cells with medical history, risk factors and medication intake in patients with advanced carotid atherosclerosis lesions.

  Clinical variables   N=134        RXR-α expression in macrophages   RXR-α expression in smooth muscle cells                                         
  -------------------- ------------ --------------------------------- ----------------------------------------- ----------- ------------ ------------ -----------
                                    62 (46)                           72 (54)                                               70 (52)      64 (48)      
  **Age (mean ±SD)**   71.02±7.98   70.98±7.67                        70.90±8.28                                0.966       70.61±8.51   71.29±7.38   0.846
  **Gender**                                                                                                    0.800                                 **0.071**
  Male                 109 (81)     51 (38)                           58 (43)                                               61 (46)      48 (36)      
  Female               25 (19)      11 (8)                            14 (11)                                               9 (7)        16 (12)      
  **Carotid**                                                                                                   0.806                                 0.774
  Right                75 (56)      34 (25)                           41 (31)                                               40 (30)      35 (26)      
  Left                 59 (44)      28 (21)                           31 (23)                                               30 (22)      29 (22)      
  **Stenosis grade**                                                                                            0.165                                 **0.015**
  \<90%                67 (50)      27 (20)                           40 (30)                                               28 (21)      39 (29)      
  ≥90%                 67 (50)      35 (26)                           32 (24)                                               42 (31)      25 (19)      
  **Diabetes**                                                                                                  0.466                                 0.898
  No                   97 (72)      43 (32)                           54 (40)                                               51 (38)      46 (34)      
  Yes                  37 (28)      19 (14)                           18 (13)                                               19 (14)      18 (13)      
  **Hyperlipidemia**                                                                                            **0.048**                             0.142
  No                   44 (33)      15 (11)                           29 (22)                                               19 (14)      25 (19)      
  Yes                  90 (67)      47 (35)                           43 (32)                                               51 (38)      39 (29)      
  **Hypertension**                                                                                              0.049                                 0.771
  No                   32 (24)      10 (7)                            22 (16)                                               16 (12)      16 (12)      
  Yes                  102 (76)     52 (39)                           50 (37)                                               54 (40)      48 (36)      
  **Smoking status**                                                                                            0.894                                 0.995
  No                   44 (33)      20 (15)                           24 (18)                                               23 (17)      21 (16)      
  Yes                  90 (67)      42 (31)                           48 (36)                                               47 (35)      43 (32)      
  **Statins**                                                                                                   0.662                                 0.698
  No                   86 (64)      41 (31)                           45 (34)                                               46 (34)      40 (30)      
  Yes                  48 (36)      21 (16)                           27 (20)                                               24 (18)      24 (18)      
  **Antiplateles**                                                                                              0.184                                 0.735
  No                   94 (70)      47 (35)                           47 (35)                                               50 (37)      44 (33)      
  Yes                  40 (30)      15 (11)                           25 (19)                                               20 (15)      20 (15)      
  **ACEs**                                                                                                      0.557                                 0.892
  No                   72 (54)      35 (26)                           37 (28)                                               38 (28)      34 (25)      
  Yes                  62 (46)      27 (20)                           35 (26)                                               32 (24)      30 (22)      
  **CAD**                                                                                                       0.449                                 0.552
  No                   76 (57)      33 (25)                           43 (32)                                               38 (28)      38 (28)      
  Yes                  58 (43)      29 (22)                           29 (22)                                               32 (24)      26 (19)      
  **PAD**                                                                                                       0.732                                 0.795
  No                   97 (72)      44 (33)                           53 (40)                                               50 (37)      47 (35)      
  Yes                  37 (28)      18 (13)                           19 (14)                                               20 (15)      17 (13)      
  **CABG/PTCA**                                                                                                 0.963                                 0.517
  No                   97 (72)      45 (34)                           52 (39)                                               49 (37)      48 (36)      
  Yes                  37 (28)      17 (13)                           20 (15)                                               21 (16)      16 (12)      
  **Symptoms**                                                                                                  0.200                                 0.239
  No                   62 (46)      25 (19)                           37 (28)                                               29 (22)      33 (25)      
  Yes                  72 (54)      37 (28)                           35 (26)                                               41 (31)      31 (23)      

###### 

Associations of PPAR-γ and RXR-α expression in macrophages and smooth muscle cells with plasma homocysteine and CRP levels of patients with advanced carotid atherosclerosis lesions.

  Clinical variables                          N=123     Homocysteine levels   CRP levels                               
  ------------------------------------------- --------- --------------------- ------------ ------- --------- --------- -----------
                                                        60 (49)               63 (51)              61 (50)   62 (50)   
  **PPAR-γ expression macrophages**                                                        0.245                       **0.038**
  Low (%)                                     64 (52)   28 (23)               36 (29)              26 (21)   38 (31)   
  High (%)                                    59 (44)   32 (26)               27 (22)              35 (28)   24 (20)   
  **PPAR-γ expression smooth muscle cells**                                                0.943                       0.242
  Low (%)                                     66 (54)   32 (26)               34 (28)              29 (24)   36 (29)   
  High (%)                                    57 (46)   28 (23)               29 (24)              32 (26)   26 (21)   
  **RXR-α expression macrophages**                                                         0.537                       0.419
  Low (%)                                     58 (47)   30 (24)               28 (23)              31 (25)   27 (22)   
  High (%)                                    65 (53)   30 (24)               35 (28)              30 (24)   35 (28)   
  **RXR-α expression smooth muscle cells**                                                 0.310                       0.791
  Low (%)                                     66 (54)   35 (28)               31 (25)              32 (26)   34 (28)   
  High (%)                                    57 (46)   25 (20)               32 (26)              29 (24)   28 (23)   
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